Gottfried E. Konecny

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract CT260: Pembrolizumab and epigenetic modification with azacitidine reprogram the tumor microenvironment of platinum-resistant epithelial ovarian cancer: clinical and translational findings from a phase II study

  Cancer Research · 2026-04-17

• Abstract 1402: Real world clinical outcomes with trastuzumab deruxtecan in HER2 expressing ovarian and endometrial cancer.

  Cancer Research · 2026-04-03

• Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

  Nature Communications · 2026-04-01

• 525 Functional Assessment of Homologous Recombination Deficiency in Ovarian Cancer via PLA-Based Immunofluorescence

  Laboratory Investigation · 2026-03-01

• Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

  Communications Medicine · 2026-02-06

• Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy

  JAMA Oncology · 2026-01-02 · 2 citations

• Phase II Study of Abemaciclib Combined with Endocrine Therapy in Low-Grade Serous Ovarian Cancer and Estrogen Receptor–Positive Endometrial CancerPreprint

  SSRN Electronic Journal · 2026-01-01

• Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2–targeted antibody–drug conjugates in breast and ovarian cancer

  Current Opinion in Obstetrics & Gynecology · 2025-12-04 · 1 citations

• Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Supplemental Table 4 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

  2025-11-25

• Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

  2025-11-25

• Supplemental Table 3 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

  2025-11-25

• RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY

  International Journal of Gynecological Cancer · 2025-11-01